Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
Morimoto K, Yamada T, Kawachi H, Tamiya M, Negi Y, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Nishioka N, Katayama Y, Iwasaku M, Tokuda S, Kijima T, Takayama K.
Morimoto K, et al. Among authors: yamada t.
Target Oncol. 2023 Nov;18(6):915-925. doi: 10.1007/s11523-023-01012-1. Epub 2023 Oct 30.
Target Oncol. 2023.
PMID: 37902896